PRESS-RELEASE ·Filed Oct 5, 2026
Press release · Contract
Actionable Insight • Neutral
Routine new-hire inducement grants — no read-through for operations or pipeline. Monitor upcoming quarterly results for clinical trial updates on ficerafusp alfa.
Latest settled — T+5d
BCAX ▲ +0.23% at T+5d
NEUTRAL call +0.23% · α vs SPY -0.19% · entry $17.29 → $17.33
Latest observation: T+14 +16.21% FF3 residual α
T+1d
-4.22%
call -4.22% · α -4.77%
$16.56
settled 21d ago
T+5d
+0.23%
call +0.23% · α -0.19%
$17.33
settled 15d ago
T+20d
Pending
in 6d
T+60d
Pending
in 2mo
Price Chart
Loading chart...
Executive Summary
Bicara Therapeutics granted inducement stock options for 207,150 shares to two new employees under its 2026 Inducement Plan. This is a routine equity grant for new hires, not a material corporate event.
Key Facts
- Inducement grants awarded on October 1, 2026 to two new employees
- Aggregate of 207,150 non-qualified stock options
- Exercise price of $18.20 per share (closing price on grant date)
- Options vest over 4 years (1/4 on first anniversary, then quarterly)
- Grants made outside stockholder-approved plans under Nasdaq Rule 5635(c)(4)
Financial Impact
Minimal — 207,150 options represent less than 0.5% of outstanding shares (based on typical clinical-stage biotech share count); no cash impact.
dilution
Risk Factors
- No material risk from this filing; standard equity compensation practice
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3374533 |
23 reports for BCAX
33% Hit rate @ T+20 Went positive at some point 1 of 3 best @ T+20▲ +5.65%
Filters
Rows
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 7, 2026 19d ago | SC 13G/A | $16.42 | awaiting T+20 | — | $16.89 (+2.86%) |
Oct 5, 2026 21d ago | Press Release | $17.29 | awaiting T+20 | — | $16.89 (−2.31%) |
Sep 22, 2026 4w ago | Institutional Cluster | $22.78 $18.35 | ▼ −19.45% | ▼ −18.89% | $16.89 (−25.86%) |
Aug 25, 2026 8w ago | 8-K | $24.73 $19.78 | ▼ −20.02% | ▼ −20.24% | $16.89 (−31.70%) |
Aug 14, 2026 10w ago | Press Release | $24.28 $23.20 | ▼ −4.45% | ▼ −2.46% | $16.89 (−30.44%) |
Aug 12, 2026 10w ago | Insider Cluster | $23.63 $22.81 | ▼ −3.47% | ▼ −1.72% | $16.89 (−28.52%) |
Aug 12, 2026 10w ago | Insider Cluster | $23.63 $22.81 | ▼ −3.47% | ▼ −1.72% | $16.89 (−28.52%) |
Aug 11, 2026 10w ago | 8-K | $23.76 $23.64 | ▼ −0.51% | ▲ +0.55% | $16.89 (−28.91%) |
Aug 11, 2026 10w ago | Press Release | $23.76 $23.64 | ▼ −0.51% | ▲ +0.55% | $16.89 (−28.91%) |
Jul 14, 2026 14w ago | Insider Cluster | $28.12 $24.63 | ▼ −12.40% | ▼ −14.74% | $16.89 (−39.93%) |
Showing 10 of 23
US Market Status
Market Closed — Opens in 3h 55m
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers